AbbVie and Genmab announced that Epkinly failed to prolong overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The multicenter study enrolled patients who had received at least one prior therapy and did not meet its primary overall‑survival endpoint, the companies reported. The result represents a late‑stage clinical setback for the program and will shape near‑term development and regulatory plans. Epkinly’s Phase 3 outcome will force AbbVie and Genmab to reassess regulatory filings and commercial expectations for the asset. Company statements indicate detailed analyses of subgroup and secondary endpoint data are underway; sponsors typically share those details with regulators and investors if they show clinically meaningful signals. For industry readers: overall survival (OS) is the gold‑standard endpoint in oncology trials and failing OS often halts advancement or prompts reevaluation of target populations and combination strategies.